Table 2.
Survival analysis of 459 GC patients in this study.
| variables | median OS (mo) | χ2-value | univariate p-value | HR value | multivariate p-value | AIC value |
|---|---|---|---|---|---|---|
| gender | ||||||
| male | 22 | 0.633 | 0.426 | |||
| female | 20 | |||||
| age at surgery (years) | ||||||
| ≤60 | 20 | 0.007 | 0.934 | |||
| >60 | 23 | |||||
| tumour location | ||||||
| upper third | 21 | 7.685 | 0.053 | |||
| middle third | 18 | |||||
| lower third | 24 | |||||
| ≥2/3 stomach | 16 | |||||
| tumour size (cm) | ||||||
| <4.0 | 26 | 4.429 | 0.035 | |||
| ≥4.0 | 21 | |||||
| Lauren classification | ||||||
| intestinal | 26 | 5.576 | 0.062 | |||
| diffuse | 20 | |||||
| mixed | 17 | |||||
| depth of tumour invasion (T stage) | ||||||
| T1 | 70 | 41.108 | <0.001 | 1.510 (1.275–1.788) | <0.001 | 81.839 |
| T2 | 27 | |||||
| T3 | 24 | |||||
| T4 | 12 | |||||
| number of metastatic lymph nodes (N stage) | ||||||
| N0 | 37 | 101.047 | <0.001 | 1.548 (1.396–1.716) | <0.001 | 101.178 |
| N1 | 23 | |||||
| N2 | 18 | |||||
| N3 | 10 | |||||
| location of lymph node metastasis | ||||||
| no | 37 | 49.837 | <0.001 | |||
| perigastric | 20 | |||||
| extragastric | 17 | |||||
| methylated CpG site count | ||||||
| 2 or less | 24 | 5.218 | 0.022 | 1.263 (1.033–1.544) | 0.023 | 78.396 |
| 3 or more | 20 | |||||
| methylated status of CpG +79 | ||||||
| unmethylated | 24 | 5.880 | 0.015 | |||
| methylated | 20 | |||||